Company intelligence / Profile preview
Humanigen
Burlingame, California, United Stateshumanigen.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Humanigen develops proprietary monoclonal antibodies using its Humaneered® technology. Its lead candidate, lenzilumab, targets GM-CSF and has been evaluated in late-stage clinical trials for COVID‑19 and hematologic cancers. The company also develops ifabotuzumab targeting EphA3 for solid tumors. Lenzilumab showed promise in reducing cytokine storm in severe COVID‑19 but did not meet all endpoints in pivotal studies. Programs continue for rare leukemias with orphan drug designations sought.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Monoclonal antibodies (mAbs)Recombinant antibodies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Humanigen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Humanigen.